Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, June 25, 2024 · 722,690,480 Articles · 3+ Million Readers

Plasma Protein Therapeutics Market Updates : Asia-Pacific Region to Grow at Highest CAGR of 6.0 % During 2022-2031

Plasma Protein Therapeutics Market

Plasma Protein Therapeutics Market1

Plasma protein therapeutics market is expected to grow as a result of factors including an increase in R&D activities related to plasma protein therapeutics.

Technological advancement is a major opportunity for the growth of the plasma protein therapeutics market.”
— Allied Market Research

WILMINGTON, DELAWARE , UNITED STATES, June 11, 2024 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, “Plasma Protein Therapeutics Market," The plasma protein therapeutics market was valued at $26.5 billion in 2021, and is estimated to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/A12692

The global plasma protein therapeutics market is expanding due to a number of factors, including the increasing adoption of key strategies by key players, the number of product approvals and launches, and the increased demand for advanced therapeutics brought on by the rise in autoimmune disorders and other chronic diseases as well as the surge in demand for efficient treatment solutions. The market for plasma protein treatments is anticipated to grow slowly, although, due to stringent laws governing the handling of plasma protein products. Conversely, during the course of the forecast period, the market for plasma protein therapies is anticipated to expand through lucrative chances brought about by the rapid improvement of technology.

The market is segmented into categories based on the kind of product, including coagulation factor, albumin, plasma-derived factor VIII, immunoglobulin, and others. The market for plasma protein therapeutics was dominated by the immunoglobulin segment in 2021. This segment is anticipated to grow at the highest rate over the forecast period due to the availability of more innovative immunoglobulin products and advancements in therapeutic administration, including subcutaneous immunoglobulin products.

The market study for plasma protein treatments is divided into categories based on application, including primary immunodeficiency, idiopathic thrombocytopenia purpura, hemophilia, and others. Due to the growth in hemophilia diagnoses and the expansion of plasma protein therapies choices, the hemophilia sector held a dominant market share in the plasma protein therapeutics market in 2021.

Because more people are being diagnosed with hemophilia and there are more options for plasma protein therapeutics, the hemophilia segment, which accounted for nearly three-fifths of the global plasma protein therapeutics market revenue in 2021, is expected to maintain its leadership position over the course of the forecast period. The primary immunodeficiency disorder sector is anticipated to have the greatest compound annual growth rate (CAGR) of 5.8% between 2022 and 2031. This might be attributed to increased awareness about the usage of plasma protein therapies for treating primary immunodeficiencies and their high prevalence.

𝐃𝐨 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐄𝐧𝐪𝐮𝐢𝐫𝐲 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 https://www.alliedmarketresearch.com/purchase-enquiry/A12692

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: -
Octapharma Ag
Grifols, S.A.
Baxter International Inc.
Adma Biologics Inc
Bio Products Laboratory Ltd
Takeda Pharmaceutical Company Limited
CSL Limited
Kedrion, Spa
Taibang Biological Group Co., Ltd
Bayer AG

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 (𝐁𝐨𝐨𝐤 𝐍𝐨𝐰 𝐰𝐢𝐭𝐡 10% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭):
𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐂𝐥𝐚𝐦𝐩𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/surgical-clamps-market-A13381
𝐒𝐩𝐞𝐞𝐜𝐡 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/speech-therapy-market-A31451

David Correa
Allied Market Research
email us here
+ 18007925285
Visit us on social media:
Facebook
Twitter
LinkedIn

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release